Rashmin C. Savani Recognized for Career Achievements by Hellenic Society of Biochemistry and Molecular Biology

September 22, 2026

The Hellenic Society of Biochemistry and Molecular Biology presented two scientific achievement awards to Rashmin C. Savani, Head of Azome Therapeutics’ Scientific Advisory Board, last month in Eretria, Greece.

Currently Professor, Nemours Eminent Scholar and Chair of Pediatrics at the University of Florida College of Medicine, Dr. Savani was recognized during the 2026 FEBS Advanced Lecture Course, where he also presented a talk on RHAMM as a link between extracellular matrix remodeling and innate immune activation and Angiogenesis.

The awards include the Society’s Award of Scientific Excellence in recognition of Dr. Savani’s distinguished scientific career and outstanding contributions to the advancement of Biochemistry, Molecular Biology, and Extracellular Matrix Research. Additionally, the Society’s Hellenic Matrix Biology Section presented Dr. Savani with an award for his significant contribution and scientific achievements in the fields of extracellular matrices and translational medicine.

About Azome Therapeutics

Azome Therapeutics is focused on developing selective RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including pulmonary and neuroinflammatory diseases. The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade. Last year, the company entered into a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) to investigate AZM-152 in bronchopulmonary dysplasia (BPD).